DOCSLIB.ORG

2020 Annual Meeting Scientific Program Committee All Relationships Are Considered Compensated

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
2020 Annual Meeting Scientific Program Committee All Relationships Are Considered Compensated 2020 Annual Meeting Scientific Program Committee All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution Stock and Other Travel, (OPTIONAL) Consulting or Advisory Patents, Royalties, Other Expert Other Name Employment Leadership Ownership Honoraria Speakers' Bureau Research Funding Accommodations, Uncompensated Role Intellectual Property Testimony Relationship Interests Expenses Relationships Howard A. Burris III HCA Healthcare / HCA Healthcare HCA Healthcare / AstraZeneca (Inst), Agios (Inst), Arch (Inst), Arvinas (Inst), Novartis Sarah Cannon / Sarah Cannon Sarah Cannon Boehringer Ingelheim AstraZeneca (Inst), BioAtla (Inst), (Inst), Bristol-Myers BioMed Valley Discoveries (Inst), Squibb (Inst), Celgene Boehringer Ingelheim (Inst), Bristol- (Inst), Eisai (Inst), FORMA Myers Squibb (Inst), Celgene (Inst), Therapeutics (Inst), Incyte CicloMed (Inst), CytomX Therapeutics (Inst), Janssen (Inst), (Inst), eFFECTOR Therapeutics MedImmune (Inst), (Inst), Gilead Sciences (Inst), Mersana (Inst), Novartis GlaxoSmithKline (Inst), Harpoon (Inst), Roche/Genentech Therapeutics (Inst), Immunocore (Inst), Tolero (Inst), Incyte (Inst), Janssen (Inst), Pharmaceuticals (Inst) Jiangsu Hengrui Medicine (Inst), Jounce Therapeutics (Inst), Kyocera (Inst), Lilly (Inst), Loxo (Inst), Macrogenics (Inst), MedImmune (Inst), Merck (Inst), Millennium (Inst), Moderna Therapeutics (Inst), Novartis (Inst), Revolution Medicines (Inst), Roche/Genentech (Inst), Seattle Genetics (Inst), Takeda (Inst), Tesaro (Inst), TG Therapeutics (Inst), Verastem (Inst), Vertex (Inst) Suzanne George Abbott Laboratories, Bayer, Blueprint ARIAD (Inst), Bayer (Inst), Blueprint UptoDate Bayer Research to Abbvie (I), Allergan Medicines, Deciphera, Medicines (Inst), Deciphera (Inst), Practice (I) Lilly, MORE Health, Novartis (Inst), Pfizer (Inst) Research to Practice, UpToDate Norah L. Henry Abbvie (Inst), Innocrin Pharma (Inst), Pfizer (Inst) Melissa L. Johnson Araxes Pharma (Inst), Abbvie (Inst), Acerta Pharma (Inst), Abbvie, Astellas Astellas Pharma (I), Adaptimmune (Inst), Amgen (Inst), Pharma, AstraZeneca, AstraZeneca (Inst), Array BioPharma (Inst), AstraZeneca Boehringer Ingelheim, BeiGene (Inst), (Inst), BeiGene (Inst), BerGenBio Bristol-Myers Squibb, Boehringer Ingelheim (Inst), Birdie (Inst), Boehringer Clovis Oncology, Daiichi (Inst), Bristol-Myers Ingelheim (Inst), Bristol-Myers Squibb Sankyo, EMD Serono, Squibb (Inst), Calithera (Inst), Checkpoint Therapeutics (Inst), Exelixis, Genentech, Biosciences (Inst), Clovis Oncology (Inst), Corvus Incyte, Merck, Pfizer, Celgene (Inst), Pharmaceuticals (Inst), CytomX Sysmex, Vapotherm Genentech/Roche (Inst), Therapeutics (Inst), Daiichi Sankyo Guardant Health (Inst), (Inst), Dynavax (Inst), EMD Serono Incyte (Inst), Loxo (Inst), (Inst), Foundation Medicine (Inst), G1 Merck (Inst), Mersana Therapeutics (Inst), (Inst), Mirati Therapeutics Genentech/Roche (Inst), Genmab (Inst), Otsuka (I), Pfizer (Inst), Genocea Biosciences (Inst), (Inst), Ribon Therapeutics GlaxoSmithKline (Inst), Gritstone (Inst), Sanofi (Inst) Oncology (Inst), Guardant Health (Inst), Hengrui Pharmaceutical (Inst), Incyte (Inst), Janssen (Inst), Kadmon (Inst), Lilly (Inst), Loxo (Inst), Lycera (Inst), Merck (Inst), Mersana (Inst), Mirati Therapeutics (Inst), Neovia Oncology (Inst), Novartis (Inst), OncoMed (Inst), Pfizer (Inst), Regeneron (Inst), Sanofi (Inst), Shattuck Labs (Inst), Stem CentRx (Inst), Syndax (Inst), Takeda (Inst), Tarveda Therapeutics (Inst) Biostatistics Karla V. Ballman Agenus, ARIAD, Prostate cancer signature Janssen Medtronic, Takeda patent (Inst), Immune Oncology, Lilly enrichment signature for response to trastuzumab in HER2+ breast cancer (Inst) Thomas Braun Johnson & OncoImmune Johnson (I) Suzanne E. AstraZeneca Patent pending for a Dahlberg statistical model assessing tumor growth (Inst) Rosemarie Mick Editas Medicine Infiniti Medical Mary W. Redman Ignyta Yu Shyr Aduro Biotech, Royalty for TNBCType for GlaxoSmithKline, Janssen Insight Genetics. TNBCType Research & Development, is a web-based subtyping Novartis, Pfizer, tool TNBCtype for candidate Roche/Genentech TNBC samples using our gene expression meta data and classification method. Nolan Wages Abbvie (Inst) Breast Cancer - Metastatic Adam Brufsky Agendia, Bayer, Bioarray Therapeutics, BioTheranostics, Celgene, Eisai, Genentech/Roche, Genomic Health, Lilly, Merck, Myriad Pharmaceuticals, NanoString Technologies, Novartis, Pfizer, Puma Biotechnology Roisin M. Connolly Genentech/Roche (Inst), Macrogenics Genentech/Roche, (Inst), Merck (Inst), Merrimack (Inst), Syndax Novartis (Inst), Puma Biotechnology (Inst) Olwen M. Hahn Via Oncology Cardinal Health (I) Pfizer Cardinal Health (I) Erika P. Hamilton Boehringer Ingelheim Abbvie (Inst), Acerta Pharma (Inst), Amgen, AstraZeneca, (Inst), Cascadian ArQule (Inst), AstraZeneca (Inst), Bayer, Bristol-Myers Therapeutics (Inst), BerGenBio (Inst), Boehringer Squibb, Clovis Daiichi Sankyo (Inst), Ingelheim (Inst), Cascadian Oncology, Eisai, EMD Eisai (Inst), Therapeutics (Inst), Clovis Oncology Serono, Foundation Genentech/Roche (Inst), (Inst), Curis (Inst), CytomX Medicine, Genentech, Lilly (Inst), Mersana (Inst), Therapeutics (Inst), Daiichi Sankyo Genentech/Roche, Pfizer (Inst), Puma (Inst), Deciphera (Inst), eFFECTOR Genzyme, Guardant Biotechnology (Inst) Therapeutics (Inst), Eisai (Inst), EMD Health, Helsinn Serono (Inst), Fujifilm (Inst), Therapeutics, HERON, Genentech/Roche (Inst), H3 Lexicon, Lilly, Biomedicine (Inst), Hutchison Medivation, Merck, MediPharma (Inst), Immunomedics Novartis, Pfizer, Roche, (Inst), InventisBio (Inst), Kadmon Sysmex, Tesaro (Inst), Leap Therapeutics (Inst), Lilly (Inst), Lycera (Inst), Macrogenics (Inst), Mallinckrodt (Inst), MedImmune (Inst), Medivation (Inst), Mersana (Inst), Merus (Inst), Millennium (Inst), Novartis (Inst), Nucana (Inst), OncoMed (Inst), Oncothyreon (Inst), Pfizer (Inst), PharmaMar (Inst), Radius Health (Inst), Regeneron (Inst), Rgenix (Inst), Stem CentRx (Inst), Syndax (Inst), Syros Pharmaceuticals (Inst), Taiho Pharmaceutical (Inst), Takeda (Inst), TapImmune (Inst), Tesaro (Inst), TetraLogic Pharmaceuticals (Inst), Verastem (Inst), Zymeworks (Inst) Elizabeth C. Reed Pfizer Pfizer/NCCN Nicholas C. Turner AstraZeneca, Bicycle AstraZeneca (Inst), Bio-Rad (Inst), Therapeutics, Bristol- Clovis Oncology (Inst), Guardant Myers Squibb, Lilly, Merck Health (Inst), Pfizer (Inst), Roche Sharp & Dohme, Novartis, (Inst) Pfizer, Roche, Tesaro Breast Cancer -Local/Regional/Adjuvant Lior Z. Braunstein Naamit K. Gerber OncLive Eun-Sil S. Hwang Henry M. Kuerer Cardinal Health, Genomic PER Genomic Health (Inst) NEJM Group, McGraw-Hill Health, Targeted Medical Publishing Education Erica L. Mayer Context Therapeutics, Myriad Genetics (Inst), Pfizer (Inst) Eisai, Lilly, Novartis, Pfizer Vered Stearns Iridium Therapeutics Abbvie, Biocept, MedImmune, Immunomedics Novartis, Pfizer, Puma Biotechnology Richard C. Zellars Cancer Prevention, Risk Reduction, and Genetics John R. Goffin Amgen, Boehringer AstraZeneca Ingelheim, Bristol-Myers Squibb, Merck Erin W. Hofstatter UpToDate Andrew McKenzie Mark E. Robson AstraZeneca AstraZeneca, McKesson Abbvie (Inst), AstraZeneca (Inst), AstraZeneca, Pfizer Clinical Care Daiichi Sankyo, Merck, InVitae (Inst), Medivation (Inst), Options, Physician Pfizer Myriad Genetics (Inst), Tesaro (Inst) Education Resource, Research to Practice Nadine M. Tung AstraZeneca Care Delivery and Regulatory Policy Adam P. Dicker American Oncohost Apex, Celldex, Cybrexa Prostate Cancer Foundation We recently filed a patient: Wilson, Socini EMD Serono, Ferring, Dreamit Ventures Google Society for Therapeutics, EMD "doped beo compounds for Merck, Self Care Radiation Serono, Janssen, optically stimulated Catalyst Oncology, Johnson & Johnson, luminescence (OSL) and Department of Oncohost, Roche, Self thermoluminescence (TL) Defense- Care Catalyst, Thirdbridge radiation dosimetry" Prostate Cancer Research Program, NRG Oncology Lynn J. Howie Ipsen National Breast Cancer Coalition Richard T. Lee Tracon (Inst) Grow Ohio Pharmaceuticals Enrique Soto Perez Roche (I) De Celis Ari Vanderwalde Bristol-Myers Squibb, Amgen (Inst), Merck (Inst), Genentech/Roche, Caris Genentech/Roche (Inst), Millennium Life Sciences, Compugen, (Inst), AstraZeneca (Inst), Polynoma Immunocore, Concerto (Inst), Lilly (Inst), Bristol-Myers Squibb Health-AI, Elsevier (Inst), Amgen (Inst), Replimune (Inst), Caris Life Sciences (Inst), EMD Serono (Inst) Central Nervous System Tumors E. Antonio Chiocca DNAtrix Merck Advantagene, Alcyone Amgen Patents related to oncolytic Lifesciences, DNAtrix, virus technology, gene Insigthec, NanoTX, therapy, microRNA, Oncorus, Sigilon, exosome, antibodies StemGen, Tocagen, ZIOPHARM Oncology Timothy F. Notable Labs Abbvie, Agios, Alexion U.S. Provisional Application Global Coalition for Cloughesy Pharmaceuticals, Bayer, No.: 62/819,322 Adaptive Research Boehringer Ingelheim, Title: COMPOSITIONS AND 501(c)(3) Boston Biomedical, Bristol- METHODS FOR TREATING Myers Squibb, Celgene, CANCER Cortice, Deciphera, Filing Date: March 15, 2019 DelMar Pharmaceuticals, Inventor(s): David A. Genocea Biosciences, Nathanson et al. GW Pharmaceuticals, FH Reference No.: UCH- Human Longevity, Insys 17760 (32246-17760) Therapeutics, KIYATEC, Your Reference No.: [UCLA Lilly, Merck, NewGen 2019-630-1] US Therapeutics, Notable Labs, Novartis, Novocure, Novogen, Oxigene, Pfizer, Puma Biotechnology, Roche/Genentech, Sunovion, Tocagen,
Load more

Recommended publications
  • Biotechnology Worldwide
    Biotechnology Worldwide There are several countries that are making special efforts to both develop and capitalise on Biotechnology. Chief amongst them is America, though cutting edge work is also going on in the UK, Ireland, Germany, Korea, Singapore, China and Japan. • America is the world leader in biotechnology, it has 1,379 biotechnology companies and employs 174,000 people. It spends £9 billion on research into biotechnology. • The European market for goods and services dependent on biotechnology is currently estimated at £30 billion and is forecast to exceed £100 billion by the year 2005 • The UK leads Europe in biotechnology and employs 19,000 people • The UK has 300 dedicated biotechnology companies and a further 250-300 involved in broader bioscience related activities • The industrial sectors which stand to benefit from biotechnology are pharmaceutical, agriculture, food and drink, chemicals and environmental technologies • Germany is the second strongest country in Europe, with 332 companies but fewer products in development than the UK. UK The UK biotechnology industry is regarded as second only to the huge effort taking place in the States. UK biotechnology companies generate over a billion pounds in revenue; half of this is pumped back into research and development. The industry has particular strengths, for example: • Britain was a key player in the world wide project of sequencing the 30,000 genes of the human genome. The announcement of the first working draft of the human genome marks a significant step forward in our understanding of the way in which we understand and develop treatments for incurable genetic conditions.
    [Show full text]
  • Etf-Sparpläne
    ETF-SPARPLÄNE ISIN NAME IE00B8KGV557 ISHARES EDGE MSCI EM MIN VOL USD (ACC) IE00B86MWN23 ISHARES EDGE MSCI EUROPE MIN VOLATILITY EUR (ACC) IE00B8FHGS14 ISHARES EDGE MSCI WORLD MIN VOLATILITY USD (ACC) IE00B6SPMN59 ISHARES EDGE S&P 500 MIN VOL USD (ACC) IE00B87G8S03 ISHARES GLOBAL AAA-AA GOV BOND USD (DIST) DE0005933931 ISHARES CORE DAX EUR (ACC) IE0032523478 ISHARES CORP BOND LARGE CAP EUR (DIST) IE00B14X4T88 ISHARES ASIA PACIFIC DIVIDEND USD (DIST) IE00B1W57M07 ISHARES BRIC 50 USD (DIST) DE000A0F5UG3 ISHARES DOW JONES EU SUSTAINABLE EUR (DIST) IE00B6R52143 ISHARES AGRIBUSINESS USD (ACC) IE00B0M62Y33 ISHARES AEX EUR (DIST) DE000A0D8Q23 ISHARES ATX EUR (DIST) IE00B1FZSC47 ISHARES USD TIPS USD (ACC) IE00B14X4S71 ISHARES USD TREASURY BOND 1-3Y USD (DIST) IE00B1FZS798 ISHARES USD TREASURY BOND 7-10Y USD (DIST) IE00B1FZSD53 ISHARES GBP INDEX-LINKED GILTS GBP (DIST) IE00B6QGFW01 ISHARES EMERGING ASIA LOCAL GOV BOND USD (DIST) IE00B5M4WH52 ISHARES JPM EM LOCAL GOV BOND USD (DIST) IE00B3DKXQ41 ISHARES EURO AGGREGATE BOND EUR (DIST) IE00B3F81R35 ISHARES CORE EURO CORP BOND EUR (DIST) IE00B4L60045 ISHARES EURO CORP BOND 1-5Y EUR (DIST) IE00B4L5ZG21 ISHARES EURO CORP BOND EX-FIN EUR (DIST) IE00B4L5ZY03 ISHARES EURO CORP BOND EX-FIN 1-5Y EUR (DIST) IE00B6X2VY59 ISHARES EURO CORP BOND INT. RATE HEDGED (DIST) IE00B14X4Q57 ISHARES EURO GOV BOND 1-3Y EUR (DIST) IE00B4WXJH41 ISHARES EURO GOV BOND 10-15Y EUR (DIST) IE00B1FZS913 ISHARES EURO GOV BOND 15-30Y EUR (DIST) IE00B1FZS681 ISHARES EURO GOV BOND 3-5Y EUR (DIST) IE00B4WXJG34 ISHARES EURO GOV BOND
    [Show full text]
  • Guidelines with Regard to the Composition, Calculation and Management of the Index
    INDEX METHODOLOGY Solactive Pharma Breakthrough Value Index Version 2.1 dated September 03, 2020 Contents Important Information 1. Index specifications 1.1 Short Name and ISIN 1.2 Initial Value 1.3 Distribution 1.4 Prices and Calculation Frequency 1.5 Weighting 1.6 Index Committee 1.7 Publication 1.8 Historical Data 1.9 Licensing 2. Composition of the Index 2.1 Selection of the Index Components 2.2 Ordinary Adjustment 2.3 Extraordinary Adjustment 3. Calculation of the Index 3.1 Index Formula 3.2 Accuracy 3.3 Adjustments 3.4 Dividends and other Distributions 3.5 Corporate Actions 3.6 Correction Policy 3.7 Market Disruption 3.8 Consequences of an Extraordinary Event 4. Definitions 5. Appendix 5.1 Contact Details 5.2 Calculation of the Index – Change in Calculation Method 2 Important Information This document (“Index Methodology Document”) contains the underlying principles and regulations regarding the structure and the operating of the Solactive Pharma Breakthrough Value Index. Solactive AG shall make every effort to implement regulations. Solactive AG does not offer any explicit or tacit guarantee or assurance, neither pertaining to the results from the use of the Index nor the Index value at any certain point in time nor in any other respect. The Index is merely calculated and published by Solactive AG and it strives to the best of its ability to ensure the correctness of the calculation. There is no obligation for Solactive AG – irrespective of possible obligations to issuers – to advise third parties, including investors and/or financial intermediaries, of any errors in the Index.
    [Show full text]
  • List of Section 13F Securities, First Quarter, 2014
    List of Section 13F Securities First Quarter FY 2014 Copyright (c) 2014 American Bankers Association. CUSIP Numbers and descriptions are used with permission by Standard & Poors CUSIP Service Bureau, a division of The McGraw-Hill Companies, Inc. All rights reserved. No redistribution without permission from Standard & Poors CUSIP Service Bureau. Standard & Poors CUSIP Service Bureau does not guarantee the accuracy or completeness of the CUSIP Numbers and standard descriptions included herein and neither the American Bankers Association nor Standard & Poor's CUSIP Service Bureau shall be responsible for any errors, omissions or damages arising out of the use of such information. U.S. Securities and Exchange Commission OFFICIAL LIST OF SECTION 13(f) SECURITIES USER INFORMATION SHEET General This list of “Section 13(f) securities” as defined by Rule 13f-1(c) [17 CFR 240.13f-1(c)] is made available to the public pursuant to Section13 (f) (3) of the Securities Exchange Act of 1934 [15 USC 78m(f) (3)]. It is made available for use in the preparation of reports filed with the Securities and Exhange Commission pursuant to Rule 13f-1 [17 CFR 240.13f-1] under Section 13(f) of the Securities Exchange Act of 1934. An updated list is published on a quarterly basis. This list is current as of March 15, 2014, and may be relied on by institutional investment managers filing Form 13F reports for the calendar quarter ending March 31, 2014. Institutional investment managers should report holdings--number of shares and fair market value--as of the last day of the calendar quarter as required by [ Section 13(f)(1) and Rule 13f-1] thereunder.
    [Show full text]
  • Mount Allison University Endowment Fund Holdings As of December 31, 2017
    Mount Allison University Endowment Fund Holdings As of December 31, 2017 Security Name Market Value ($Can) EQUITY HOLDINGS Canadian Holdings 5N PLUS INC $ 155 ABSOLUTE SOFTWARE CORP $ 851 ACADIAN TIMBER CORP $ 302 ADVANTAGE OIL & GAS LTD $ 283,788 AECON GROUP INC $ 1,728 AFRICA OIL CORP $ 684 AG GROWTH INTERNATIONAL INC $ 1,163 AGELLAN COMMERCIAL REAL ESTATE $ 349 AGF MANAGEMENT LTD $ 990 AGNICO-EAGLE MINES LTD $ 427,207 AGT FOOD AND INGREDIENTS INC $ 653 AIMIA INC $ 832 AIR CANADA INC $ 325,411 AIRBOSS OF AMERICA CORP $ 315 ALACER GOLD CORP $ 1,289 ALAMOS GOLD INC $ 2,216 ALAMOS GOLD INC NEW COM CLASS A $ 4,877 ALARIS ROYALTY CORP $ 1,107 ALGOMA CENTRAL CORP $ 330 ALIMENTATION COUCHE-TARD INC $ 98,854 ALIO GOLD INC $ 472 ALLIED PROPERTIES REAL ESTATE INVESTMENT TRUST $ 2,575 ALTIUS MINERALS CORP $ 1,233 ALTUS GROUP LTD/CANADA $ 1,916 ANDREW PELLER LTD $ 1,448 ARGONAUT GOLD INC $ 656 ARTIS REAL ESTATE INVESTMENT TRUST $ 1,539 ASANKO GOLD INC $ 209 ATCO LTD $ 119,947 ATHABASCA OIL COP $ 703 ATS AUTOMATION TOOLING SYSTEMS INC $ 1,769 AURICO METALS INC $ 311 AUTOCANADA INC $ 1,128 AVIGILON CORP $ 1,258 B2GOLD CORP $ 29,898 BADGER DAYLIGHTING LTD $ 1,525 BANK OF MONTREAL $ 725,449 BANK OF NOVA SCOTIA $ 2,019,757 BARRICK GOLD CORP $ 459,749 BAYTEX ENERGY CORP $ 1,213 BCE INC $ 791,441 BELLATRIX EXPLORATION LTD $ 94 BIRCHCLIFF ENERGY LTD $ 1,479 BIRD CONSTRUCTION INC $ 731 1 Mount Allison University Endowment Fund Holdings As of December 31, 2017 Security Name Market Value ($Can) BLACK DIAMOND GROUP LTD $ 95 BLACKBERRY LIMITED $ 151,777 BLACKPEARL RESOURCES INC $ 672 BOARDWALK REAL ESTATE INVESTMENT TRUST $ 1,610 BONAVISTA ENERGY CORP $ 686 BONTERRA ENERGY CORP $ 806 BORALEX INC $ 2,276 BROOKFIELD ASSET MANAGEMENT INCORPORATED $ 672,870 BROOKFIELD INFRASTRUCTURE PARTNERS L.P.
    [Show full text]
  • Biopartnering Executive Summary
    BIOWORLD® BIOPARTNERING REPORT 2009: STRATEGIES AND PARADIGMS OF THE DEAL EXECUTIVE SUMMARY By Michael Harris, BioWorld Executive Editor and Amanda Lyle, BioWorld Managing Editor LIST OF CONTENTS Introduction and Analysis Trends Depressing First Half of 2008 in Worldwide Public Markets Drug/Device Combos Could Salvage Dropped Compounds A Match Made in Heaven; R&D Productivity Via Partnering Drug and Medical Device Deals: A Different Type of Partnership As Big Pharma Model Falters, Biotech Rides to the Rescue Deals to M&As: The Culture of False-Flagging, Shape-Shifting Notable Deals Autoimmune and Inflammation Deals Immunomedics Inks Potential $620M Deal with Nycomed ARYx Seeking New Partner for GI Program after P&G Bails Out UCB Licenses Keppra, Cimzia Rights in Japan Alizyme, Norgine Team Up in $67M Marketing Deal Bionomics Signs Merck Serono in MS, Autoimmune Partnership TransPharma Gets $35M in Osteo Deal with Lilly QLT Sells Acne Gel Product Aczone for $150M to Allergan Start-up TFT Adds NF-Kappa B Decoy Program from Anesiva Early Stage Antibody Nets EUSA $44M from GSK Scil, Pfizer Enter $250M Deal for Preclinical Osteo Drug Catalyst Partners with Centocor for Engineered Protease Drugs Galapagos Inks $395M Deal with Lilly for Osteo Drugs Alba Inks Ex-U.S./Japan Deal with Shire for Celiac Drug Excaliard Snags $15.5M and Isis Fibrosis Drugs Galapagos and Janssen in RA Partnership Axcan, Cellerix Deal for Adult Stem Cell Therapy Radius Grants Novartis Option to BA058 in Potential $500M Deal Microbia, Forest Collaborate: Up to $330M for
    [Show full text]
  • Saving UK Biotech
    January 22, 2009 Saving UK Biotech Evaluate Vantage While news of the death of the UK biotechnology industry maybe exaggerated, despite a recent spate of companies falling into administration and big pharma picking off some of the best and brightest hopes in the sector, a report into the state of the industry by the Bioscience Innovation and Growth Team published today indicated that an ambulance might be called for unless drastic measures are taken. Chief among the calls from the group, which is supported by the UK’s industry champion, the Biotech Industry Association, was the need for more tax incentives, especially for the pharmaceutical industry to make investments in smaller biotechnology businesses more attractive, in order to ensure the health of the sector. Speedier approvals The National Institute for Health and Clinical Excellence (NICE), which decides on which drugs will be used in the UK’s health service was also identified as a potential barrier to drug innovation, due to the length of time it takes to decide on whether to use drugs. Sir David Cooksey, who was presenting the review on progress made in the industry since 2003, said that the average time between approval of a drug and its introduction by NICE often equated to a third of the patent life of the drug, leaving innovator companies less time to recoup the cost of drug discovery and potentially driving prices up. But the most controversial proposal today was the suggestion that drugs in phase II be used commercially in the UK, whilst waiting for approval, allowing orginators to recoup the cost of development at an earlier stage.
    [Show full text]
  • ESSAYS on the DRUG DISCOVERY INNOVATION SYSTEM By
    ESSAYS ON THE DRUG DISCOVERY INNOVATION SYSTEM by Alfred Sarkissian A Dissertation Submitted to the Graduate Faculty of George Mason University in Partial Fulfillment of The Requirements for the Degree of Doctor of Philosophy Public Policy Committee: _______________________________________ David M. Hart, Chair _______________________________________ Siona Listokin _______________________________________ Naoru Koizumi Ruben Jacobo-Rubio, External Reader _______________________________________ Sita N. Slavov, Program Director _______________________________________ Mark J. Rozell, Dean Date: __________________________________ Fall Semester 2017 George Mason University Fairfax, VA Essays on the Drug Discovery Innovation System A Dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy at George Mason University by Alfred Sarkissian Master of Arts Allameh Tabatabai University, 2002 Bachelor of Arts Azad University, 1997 Director: David M. Hart, Professor Department of Public Policy; Schar School of Policy and Government Fall Semester 2017 George Mason University Fairfax, VA Copyright 2017 Alfred Sarkissian All Rights Reserved ii ACKNOWLEDGEMENTS I need to express my deepest gratitude to my committee chair Prof. David M. Hart for his advice, mentorship, and patience in the course of this dissertation and the program. I also owe a sincere appreciation to other committee members Prof. Naoru Koizumi and Prof. Siona Listokin. Prof. Mark Addleson was forthcoming with his time during the field stage
    [Show full text]
  • Biotech Anglais270
    L’INFORMATION STRATÉGIQUE DE L’ESPACE EUROPÉEN DE L’INNOVATION Biotechnologies FINANCES IAL EC & P S TH HALF 2005S N° 270 • December 26th 2005 11 HOUR nd 2 L www.biotech-finances.com A € D E 2005: The European Giant Sommaire Stirs from Slumber 11th hour • 2005: The European Giant Stirs 2004 was a disappointment for the biotech and medtech commu- from Slumber ............................p. 1-3 nity. IPOs failed, new finance proved difficult and complicated to Special €Deals find, and attempts at consolidation were stillborn. This meant that many players and observers in the life sciences industry went into The British Isles 2005 believing that mergers and acquisitions were likely to be the • « Biotech in UK are ready to explore new business models » ..............p. 4 main salvation of biotech and medtech. • « There is a lot of interest on the Irish part in going down the IPO road on AIM » ............................p. 4 And yet, 2005 has produced a remarkably good vintage! An IPO window France opened and a number of impressive financing rounds have been achie- • « Technology Transfer has become one major stake » ......................p. 7 ved. The recovery also saw successful consolidation take place. Opportu- nism and opportunity have been the watchwords of the year. German speaking countries The wounds sustained by the biotech industry after the stock market • « Many companies have products in Phase II or Phase III » ............p. 8 bubble burst seem to be healing. Youthful exuberance has returned. More • « We remain positive about the mature projects are now being presented to investors - who themelves prospects for 2006 »......................p.
    [Show full text]
  • Public Affairs and Lobbying Register
    Public Affairs and Lobbying Register 3x1 Offices: 16a Walker Street, Edinburgh EH3 7LP 210 Borough High Street, London SE1 1JX 26-28 Exchange Street, Aberdeen, AB11 6PH OFFICE(S) Address: 3x1 Group, 11 Fitzroy Place, Glasgow, G3 7RW Tel: Fax: Web: CONTACT FOR PUBLIC AFFAIRS [email protected] LIST OF EMPLOYEES THAT HAVE CONDUCTED PUBLIC AFFAIRS SERVICES Ailsa Pender Cameron Grant Katrine Pearson Lindsay McGarvie Patrick Hogan LIST OF CLIENTS FOR WHOM PUBLIC AFFAIRS SERVICES HAVE BEEN PROVIDED Atos North British Distillery Scottish Child Abuse Inquiry SICPA The Scottish Salmon Company Viridor Public Affairs and Lobbying Register Aiken PR OFFICE(S) Address: 418 Lisburn Road, Belfast, BT9 6GN Tel: 028 9066 3000 Fax: 028 9068 3030 Web: www.aikenpr.com CONTACT FOR PUBLIC AFFAIRS [email protected] LIST OF EMPLOYEES THAT HAVE CONDUCTED PUBLIC AFFAIRS SERVICES Claire Aiken Donal O'Neill John McManus Lyn Sheridan Shane Finnegan LIST OF CLIENTS FOR WHOM PUBLIC AFFAIRS SERVICES HAVE BEEN PROVIDED Diageo McDonald’s Public Affairs and Lobbying Register Airport Operators Associaon OFFICE(S) Address: Airport Operators Association, 3 Birdcage Walk, London, SW1H 9JJ Tel: 020 7799 3171 Fax: 020 7340 0999 Web: www.aoa.org.uk CONTACT FOR PUBLIC AFFAIRS [email protected] LIST OF EMPLOYEES THAT HAVE CONDUCTED PUBLIC AFFAIRS SERVICES Ed Anderson Henk van Klaveren Jeff Bevan Karen Dee Michael Burrell - external public affairs Peter O'Broin advisor Roger Koukkoullis LIST OF CLIENTS FOR WHOM PUBLIC AFFAIRS SERVICES HAVE BEEN PROVIDED N/A Public Affairs and
    [Show full text]
  • 31 December 2018 Transition and Annual Report 2018
    TRANSITION AND ANNUAL REPORT 2018 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended OR ⌧ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from October 1, 2018 to December 31, 2018 Commission File Number 001-35892 GW PHARMACEUTICALS PLC (Exact name of Registrant as specified in its charter) England and Wales Not Applicable (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) Sovereign House, Vision Park Chivers Way, Histon Cambridge, CB24 9BZ United Kingdom +44 1223 266800 (Address of principal executive offices) (Registrant’s telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Title of each class Name of exchange on which registered American Depositary Shares, each representing 12 Ordinary The Nasdaq Global Market Shares, par value £0.001 per share Securities registered pursuant to Section 12(g) of the Act: None Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. YES ☑ NO ☐ Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. YES ☐ NO ☑ Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
    [Show full text]
  • 2019 Scientific Program Committee All Relationships Are Considered Compensated
    2019 Scientific Program Committee All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution Patents, Stock and Other Travel, Royalties, Other Expert Other Name Employment Leadership Ownership Honoraria Consulting or Advisory Role Speakers' Bureau Research Funding Accommodations, Intellectual Testimony Relationship Interests Expenses Property Monica M. Leap Syntalogic, Syntimmune Abbvie (Inst), Agenus (Inst), Astellas Pharma (Inst), AstraZeneca Bertagnolli Therapeutics (Inst), Baxalta (Inst), Bayer Health (Inst), Breast Cancer Research Foundation (Inst), Bristol-Myers Squibb (Inst), Celgene (Inst), Complion (Inst), Eisai (Inst), Exelixis (Inst), Genentech (Inst), GHI Pharma (Inst), Gilead Sciences (Inst), GlaxoSmithKline (Inst), Incyte (Inst), Janssen (Inst), Jazz Pharmaceuticals (Inst), Leidos (Inst), Lexicon (Inst), Lilly (Inst), Matrex (Inst), Mayo Clinic (Inst), Merck (Inst), MGH (Inst), Millenium Pharamceuticals (Inst), Novartis (Inst), Patient Centered Outcomes Research Institute (PCORI) (Inst), Pfizer (Inst), Pharmacyclics (Inst), Robert Wood Johnson Foundation (Inst), Sagerock Advisors (Inst), Sanofi (Inst), Taiho Pharmaceutical (Inst), Takeda (Inst), Tesaro (Inst), Teva (Inst) Suzanne George Abbott Laboratories, AstraZeneca, Bayer, Blueprint ARIAD (Inst), Bayer (Inst), Blueprint Medicines (Inst), Deciphera UptoDate Bayer Research to Abbvie (I), Allergan (I) Medicines, Deciphera, Lilly (Inst), Novartis (Inst), Pfizer (Inst) Practice Melissa
    [Show full text]